JP2002542827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542827A5 JP2002542827A5 JP2000615762A JP2000615762A JP2002542827A5 JP 2002542827 A5 JP2002542827 A5 JP 2002542827A5 JP 2000615762 A JP2000615762 A JP 2000615762A JP 2000615762 A JP2000615762 A JP 2000615762A JP 2002542827 A5 JP2002542827 A5 JP 2002542827A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000028993 immune response Effects 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 208000007190 Chlamydia Infections Diseases 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13227099P | 1999-05-03 | 1999-05-03 | |
| US60/132,270 | 1999-05-03 | ||
| US14127699P | 1999-06-30 | 1999-06-30 | |
| US60/141,276 | 1999-06-30 | ||
| PCT/CA2000/000511 WO2000066739A2 (en) | 1999-05-03 | 2000-05-03 | Chlamydia antigens and corresponding dna fragments and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002542827A JP2002542827A (ja) | 2002-12-17 |
| JP2002542827A5 true JP2002542827A5 (enExample) | 2007-03-29 |
| JP4695763B2 JP4695763B2 (ja) | 2011-06-08 |
Family
ID=26830227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000615762A Expired - Fee Related JP4695763B2 (ja) | 1999-05-03 | 2000-05-03 | クラミジア抗原および対応するｄｎａ断片ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20030095973A1 (enExample) |
| EP (1) | EP1177301B1 (enExample) |
| JP (1) | JP4695763B2 (enExample) |
| AT (1) | ATE375391T1 (enExample) |
| AU (1) | AU780444B2 (enExample) |
| CA (1) | CA2373021A1 (enExample) |
| DE (1) | DE60036698T2 (enExample) |
| WO (1) | WO2000066739A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| EP1105489A1 (en) | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Nucleic acid molecules encoding pomp91a protein of chlamydia |
| AU5366099A (en) | 1998-08-20 | 2000-03-14 | Connaught Laboratories Limited | Nucleic acid molecules encoding inclusion membrane protein of (chlamydia) |
| US6649370B1 (en) | 1998-10-28 | 2003-11-18 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US6607730B1 (en) | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| AU3790900A (en) | 1998-12-01 | 2000-06-19 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| MXPA01005615A (es) * | 1998-12-04 | 2004-08-19 | Univ Manitoba | Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia. |
| US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| CN100365120C (zh) | 1998-12-08 | 2008-01-30 | 科里克萨有限公司 | 用于治疗及诊断衣原体感染的化合物和方法 |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US7297341B1 (en) | 1998-12-23 | 2007-11-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| CA2354431A1 (en) | 1998-12-23 | 2000-07-06 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| JP2002541766A (ja) | 1998-12-28 | 2002-12-10 | アベンティス、パストゥール、リミテッド | クラミジア抗原および対応するｄｎａ断片ならびにその使用 |
| GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
| EP2172214A3 (en) | 1999-03-12 | 2011-03-16 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| WO2000066739A2 (en) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| CA2385325C (en) | 1999-09-20 | 2012-04-10 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| WO2001036455A2 (en) * | 1999-11-12 | 2001-05-25 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| EP1240331B1 (en) | 1999-12-22 | 2010-04-07 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US20020082402A1 (en) * | 2000-04-04 | 2002-06-27 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| AU2001255596A1 (en) | 2000-04-21 | 2001-11-07 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20040254130A1 (en) * | 2000-05-08 | 2004-12-16 | Murdin Andrew D | Chlamydia antigens and corresponding dna fragments and uses thereof |
| EP1282718B1 (en) | 2000-05-08 | 2006-12-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
| US20080112965A1 (en) * | 2001-10-01 | 2008-05-15 | Aventis Pasteur Limited | Chlamydia OMP antigen |
| WO2010100632A2 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
| EP2501396B1 (en) | 2009-11-18 | 2018-04-25 | Auburn University | Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1331443C (en) * | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| CN100365017C (zh) * | 1994-09-20 | 2008-01-30 | 日立化成工业株式会社 | 肺炎衣原体抗原多肽 |
| FR2726764B1 (fr) * | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
| US5840788A (en) | 1997-06-20 | 1998-11-24 | Acushnet Company | Ultraviolet light resistant urethane top coat for golf balls |
| ES2264810T3 (es) * | 1997-06-23 | 2007-01-16 | Loke Diagnostics Aps | Proteinas de chlamydia pneumoniae expuestas en la superficie. |
| US7459524B1 (en) * | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| KR20010032336A (ko) * | 1997-11-21 | 2001-04-16 | 브랑디 빠스깔 | 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
| ATE480625T1 (de) | 1997-11-21 | 2010-09-15 | Merck Serono Biodevelopment | Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion |
| KR100760221B1 (ko) | 1997-11-28 | 2007-10-30 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| AU5366099A (en) | 1998-08-20 | 2000-03-14 | Connaught Laboratories Limited | Nucleic acid molecules encoding inclusion membrane protein of (chlamydia) |
| EP1129202A2 (en) | 1998-10-28 | 2001-09-05 | Aventis Pasteur Limited | Chlamydia antigenes and corresponding dna fragments and uses thereof |
| US6822071B1 (en) * | 1998-11-12 | 2004-11-23 | The Regents Of The University Of California | Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease |
| EP1133572A4 (en) | 1998-11-12 | 2005-06-15 | Univ California | GENOME SEQUENCE OF CHLAMYDIA PNEUMONIAE |
| AU3790900A (en) | 1998-12-01 | 2000-06-19 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US6565856B1 (en) | 1998-12-08 | 2003-05-20 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| CN100365120C (zh) | 1998-12-08 | 2008-01-30 | 科里克萨有限公司 | 用于治疗及诊断衣原体感染的化合物和方法 |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
| WO2000066739A2 (en) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| CA2385325C (en) | 1999-09-20 | 2012-04-10 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| EP1240331B1 (en) | 1999-12-22 | 2010-04-07 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| AU2138501A (en) | 1999-12-22 | 2001-07-03 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020071831A1 (en) | 2000-04-04 | 2002-06-13 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020082402A1 (en) | 2000-04-04 | 2002-06-27 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20030100706A1 (en) | 2000-04-04 | 2003-05-29 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020132994A1 (en) | 2000-04-04 | 2002-09-19 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020094965A1 (en) | 2000-04-04 | 2002-07-18 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| AU2001255596A1 (en) | 2000-04-21 | 2001-11-07 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20040254130A1 (en) | 2000-05-08 | 2004-12-16 | Murdin Andrew D | Chlamydia antigens and corresponding dna fragments and uses thereof |
| EP1282718B1 (en) | 2000-05-08 | 2006-12-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
-
2000
- 2000-05-03 WO PCT/CA2000/000511 patent/WO2000066739A2/en not_active Ceased
- 2000-05-03 CA CA002373021A patent/CA2373021A1/en not_active Abandoned
- 2000-05-03 AT AT00925004T patent/ATE375391T1/de active
- 2000-05-03 DE DE60036698T patent/DE60036698T2/de not_active Expired - Lifetime
- 2000-05-03 US US09/564,479 patent/US20030095973A1/en not_active Abandoned
- 2000-05-03 EP EP00925004A patent/EP1177301B1/en not_active Expired - Lifetime
- 2000-05-03 JP JP2000615762A patent/JP4695763B2/ja not_active Expired - Fee Related
- 2000-05-03 AU AU43885/00A patent/AU780444B2/en not_active Ceased
-
2003
- 2003-06-30 US US10/608,559 patent/US7070792B2/en not_active Expired - Fee Related
-
2005
- 2005-05-02 US US11/118,381 patent/US7595058B2/en not_active Expired - Fee Related
-
2009
- 2009-02-09 US US12/367,955 patent/US7658934B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2395499A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| JP2004511201A5 (enExample) | ||
| CA2385325A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| JP2003527079A5 (enExample) | ||
| JP2003510050A5 (enExample) | ||
| JP2004501618A5 (enExample) | ||
| JP2003500040A5 (enExample) | ||
| JP2008529558A5 (enExample) | ||
| JP2005511076A5 (enExample) | ||
| JP2002537791A5 (enExample) | ||
| JP2019519252A5 (enExample) | ||
| JP2004512020A5 (enExample) | ||
| JP2000516200A (ja) | ウシの呼吸病に対するポリヌクレオチドワクチン処方 | |
| JP2007502101A5 (enExample) | ||
| CA2196555A1 (en) | Vr-2332 viral nucleotide sequence and methods of use | |
| JP2006512097A5 (enExample) | ||
| CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| JP2002533125A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| JP2003530872A5 (enExample) | ||
| JP2025094154A5 (enExample) | ||
| JP2004501646A5 (enExample) | ||
| JP2001516583A5 (enExample) | ||
| JP2003530088A5 (enExample) | ||
| JP2023522154A5 (enExample) |